"Seriously, 35% of 375 million can be a lot of money ($131 million?). But it really depends on a lot of other things going right. It is perhaps the most intangeable item of the deal. It depends on 2 compounds getting approvals, and we should not count that money yet"
I believe you missed my point completely. The 65% or 244M is attainable and some in the short period, meaning 2010. Dr. Manuso stated these words "advance previous arranged target", so they may already identified what GSK wants Climb to aim at. Now here's why the question by the analyst was important and why 65% is loaded earlier than later. Such milestones as identifying the lead compound, ph1, ph2 and ph3 all have milestones tied to them. I'm sure the higher values come with greater advancements and hitting targets. But the greater majority is not waiting on FDA approval for SUPG to receive it. I was surprised to see 65% would be earned prior to any approval, as long as they reached certain met goals. As investors we want to see additional milestones reached in this deal and prevent any additional burn and couple that with any new advances and revenues with Dacogen, would be very welcomed. IMHO.